Insider Cluster (2 insiders) ·Filed May 19, 2026

KALV

KalVista Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $58K total
Actionable Insight • Neutral

The cluster is too small to drive a trade. Monitor for larger-volume insider sales or a new catalyst (e.g., regulatory updates on sebetralstat) before taking a directional view. The cross-filing amplifiers note this cluster coincides with late-filing/offering/press context, which could amplify impact if a material event emerges, but as a standalone the dollar value is noise.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d ⚠ clustered
KALV ▼ -0.07% at T+5d
NEUTRAL call ✗ call lost -0.07% · α vs SPY -1.31% · entry $26.81 → $26.79
Next anchor: T+20d due 4mo ago
Latest observation: T+17 -10.93% FF3 residual α
Entry anchored
May 19, 04:00 PM ET
via exchange tick
T+1d
-0.15%
call -0.15% · α -0.34%
$26.77
settled 5mo ago
T+5d
-0.07%
call -0.07% · α -1.31%
$26.79
settled 4mo ago
T+20d
—
call — · α —
—
due 4mo ago
T+60d
—
call — · α —
—
due 7w ago

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.004% of $1.4B market cap) on May 18, 2026, alongside option exercises. The dollar value is immaterial relative to market cap, and the sales follow a derivative exercise pattern consistent with routine tax- or vesting-related liquidation rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$30.0K
Insiders
2

Key Facts

  • CEO Palleiko sold 1,129 shares ($30K) on May 18 at $26.76
  • CMO Audhya sold 1,032 shares ($28K) on May 18 at $26.76
  • Both insiders had exercised 2,419 derivative shares at $0 on May 17 (non-cash)
  • Total open-market sales = $58K, or ~0.004% of $1.4B market cap
  • Prior insight filings on KALV have a weak T+20 track record (-8.8% avg return)

Financial Impact

$58K total insider sales — trivial relative to $1.4B market cap

insider holdingsdilution

Risk Factors

  • A future material adverse event could make even small insider sales appear opportunistic in hindsight
  • Historical P&L on KALV reports is very weak (20% win rate at T+20) — do not extrapolate from prior call misses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KALV-1779221126099
12 reports for KALV
Performance horizon
50% Hit rate 3 of 6 directional calls best @ T+5▲ +4.15%Apr 17, 2026
Filters
Rows
Reports for KALV — sortable, filterable
TypeNow
Jun 22, 2026
14w ago
15-12G
BEARISH ★ 7/10
—awaiting T+1——
Jun 17, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$27.00 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 5/10
$26.99 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 2/10
$27.00 $27.00· 0.00%▼ −0.54%—
May 19, 2026
19w ago
Insider Cluster
BEARISH ★ 5/10
$26.81 $26.77▲ +0.15%▲ +0.34%—
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.81 $26.77▼ −0.15%▼ −0.34%—
Apr 29, 2026
22w ago
8-K
BULLISH ★ 8/10
$26.67 $26.66▼ −0.04%▼ −1.06%—
Apr 17, 2026
24w ago
Insider Cluster
BEARISH ★ 6/10
$20.48 $20.87▼ −1.90%▼ −2.10%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 19, 2026